Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 43

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 43
---
 a warrant inducement transaction in May 2024, and is subject in all respects to the provisions contained in the applicable warrants,which
are filed as exhibits to our Report on Form 6-K dated May 22, 2024. Unless otherwise stated, references to warrants in this subsection include the Series G Warrants and Warrant Agent Warrants. The Series H Warrants issued in the transaction have expired.

Exercisability. The warrants
became exercisable on May 24, 2024. The Series G Warrants and Warrant Agent Warrants
expire five years and three years, respectively, from the initial exercise date. The holder shall deliver the aggregate exercise price
for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise (subject to the ‘cashless
exercise’ arrangements described below).

Cashless Exercise. If,
at the time a holder exercises its warrants, a registration statement registering the issuance of the securities underlying the warrants
under the Securities Act is not then effective or available and an exemption from registration under the Securities Act is not available
for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in
payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the
net number of Depositary Shares determined according to a formula set forth in the warrants.

Exercise Price.The exercise
price of each Series G Warrant and Warrant Agent Warrants is $625.00 per Depositary
Share.

Beneficial Ownership Limitation. A
holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect to such exercise, such holder,
together with such holder’s affiliates, and any persons acting as a group together with such holder or any such affiliate, would
beneficially own in excess of 9.99% or 4.99%, at the holders determination, of the number of Ordinary Shares outstanding immediately
after giving effect to the issuance of the Ordinary Shares underlying the Depositary Shares upon such exercise. The holder of the warrant,
upon notice to us, may increase or decrease the beneficial ownership limitation to a percentage not to exceed 9.99%, provided that any
increase in the beneficial ownership limitation shall not be effective until 61 days following notice to us. Beneficial ownership of
the holder and its affiliates will be determined in accordance with Section 13(d